Tag Archives: Schroder Adveq

Novartis Leads $100M Round for Fibrosis-Focused Pliant Therapeutics

When Novartis signed on as a partner to Pliant Therapeutics last fall, it also agreed to eventually take an equity stake in the smaller biotech. The Swiss pharmaceutical giant made good on that commitment Tuesday, leading a $100 million investment. Besides Novartis, the Series C round of funding adds so-called crossover investors, firms that invest […]

Posted in Boston blog main, Boston top stories, National blog main, San Francisco, San Francisco blog main, San Francisco top stories | Tagged , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , | Comments Off on Novartis Leads $100M Round for Fibrosis-Focused Pliant Therapeutics

Bio Roundup: Coronavirus Concerns, Sarepta’s CRL, Eye Drug OK’d & More

Company news slowed somewhat this week, perhaps as some took the federal Martin Luther King Jr. Day holiday away from the office and others recovered from back-to-back meetings and late nights at the JP Morgan Healthcare Conference. However, a new coronavirus believed to stem from Wuhan, China, captured the attention of the world healthcare community. […]

Posted in Boston blog main, Boston top stories, Boulder/Denver blog main, Boulder/Denver top stories, Detroit blog main, Detroit top stories, Europe blog main, Europe top stories, Indiana blog main, Indiana top stories, National, National blog main, National top stories, New York blog main, New York top stories, Raleigh-Durham blog main, Raleigh-Durham top stories, San Diego blog main, San Diego top stories, San Francisco blog main, San Francisco top stories, Seattle blog main, Seattle top stories, Texas blog main, Texas top stories, Wisconsin blog main, Wisconsin top stories | Tagged , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , | Comments Off on Bio Roundup: Coronavirus Concerns, Sarepta’s CRL, Eye Drug OK’d & More

After Amgen’s Spark, Revolution Med Nabs $100M to Push RAS Cancer Drugs

In May, Amgen (NASDAQ: AMGN) revealed intriguing data from the first-ever human trial of a drug that targets tumors with a specific mutation to the gene KRAS, which occurs in about one-quarter of all cancers. Amgen showed 30 percent of lung cancer patients with the mutation saw their tumors shrink. Even though the data were […]

Posted in Boston blog main, National blog main, San Francisco, San Francisco blog main, San Francisco top stories | Tagged , , , , , , , , , , , , , , , , , , , , , | Comments Off on After Amgen’s Spark, Revolution Med Nabs $100M to Push RAS Cancer Drugs

Pliant Picks Up $62M to Test Lung, Liver Fibrosis Drug in the Clinic

The cause of fibrosis, the hardening and thickening of connective tissue in organs, isn’t known and it has few treatments. Pliant Therapeutics aims to bring patients who have this chronic and life-threatening condition in the lungs or the liver a new treatment option—and it now has $62 million to test its lead drug in humans. […]

Posted in Boston blog main, National blog main, San Francisco, San Francisco blog main, San Francisco top stories, Texas blog main | Tagged , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , | Comments Off on Pliant Picks Up $62M to Test Lung, Liver Fibrosis Drug in the Clinic

Decibel Hauls in $55M to Bring Multiple Hearing Drugs to the Clinic

[Updated, 6/19/18, 4:20 p.m. See below.] Hearing loss affects millions of Americans, but so far, drug companies have not yet brought treatments to the market. Decibel Therapeutics aims to pioneer the discovery and development of therapies addressing multiple forms of hearing loss. The startup has quietly built a pipeline of experimental drugs, and as those […]

Posted in Boston, Boston blog main, Boston top stories, National blog main, National top stories, New York blog main | Tagged , , , , , , , , , , , , , , , , , , , , , , , , , , , , | Comments Off on Decibel Hauls in $55M to Bring Multiple Hearing Drugs to the Clinic

Raising $56M, Revolution Medicines Drops Old Work and Turns to Cancer

Revolution Medicines emerged three years ago to develop drugs from products found in nature and said its lead prospect would be an antifungal compound. Redwood City, CA-based Revolution is now focused on cancer and has raised $56 million to bring a completely different drug into clinical studies. The firm is targeting an enzyme called SHP2, […]

Posted in Boston blog main, National blog main, San Francisco, San Francisco blog main, San Francisco top stories | Tagged , , , , , , , , , , , , , , , , , , , , | Comments Off on Raising $56M, Revolution Medicines Drops Old Work and Turns to Cancer